-
-
-
-
-
-
-
Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVYâ„¢
-
-
-
-
-
-
-
Vertex Pharma (VRTX) Reports Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease
-
-
-
-
-
-
-
Vertex Pharma (VRTX) Announces U.S. FDA Acceptance of sNDA for TRIKAFTA in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations
-
-
-
-
-
-
-
FDA Accepts New Drug Application for VX-445 (Elexacaftor), Tezacaftor and Ivacaftor Combination Treatment
-
-
-
-
-
-
-
Pre-Open Stock Movers 07/19: (AEZS) (VRTX) (SNI) Higher; (DRYS) (NTRS) (HDP) Lower (more...)
-
-
-
-
-
-
-
Vertex Reports Third Quarter 2015 Financial Results
-
-
-
-
12,339 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All